Tobam Lowers Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Tobam cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 62.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,784 shares of the biopharmaceutical company’s stock after selling 19,683 shares during the quarter. Tobam’s holdings in Alnylam Pharmaceuticals were worth $2,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sumitomo Mitsui Trust Group Inc. grew its position in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after acquiring an additional 8,462 shares in the last quarter. Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $41,529,000. Bleakley Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 16.9% during the fourth quarter. Bleakley Financial Group LLC now owns 2,590 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 375 shares during the last quarter. Choreo LLC increased its position in shares of Alnylam Pharmaceuticals by 8.6% during the 4th quarter. Choreo LLC now owns 4,748 shares of the biopharmaceutical company’s stock valued at $1,121,000 after purchasing an additional 378 shares during the last quarter. Finally, E. Ohman J or Asset Management AB increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. E. Ohman J or Asset Management AB now owns 6,100 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, January 21st. Sanford C. Bernstein cut their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

Insiders Place Their Bets

In related news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,964 shares of company stock worth $20,622,925. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $278.25 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The company’s fifty day moving average price is $252.31 and its 200-day moving average price is $261.81. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.